Display options
Cite
Yang H, Ma Y, Liu Z, et al. Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis. Mol Clin Oncol. 2014;3(2):420-424doi: 10.3892/mco.2014.467.
Yang, H., Ma, Y., Liu, Z., Wang, Z., Han, B., & Ma, L. (2015). Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis. Molecular and clinical oncology, 3(2), 420-424. https://doi.org/10.3892/mco.2014.467
Yang, Huizhen, et al. "Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis." Molecular and clinical oncology vol. 3,2 (2015): 420-424. doi: https://doi.org/10.3892/mco.2014.467
Yang H, Ma Y, Liu Z, Wang Z, Han B, Ma L. Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis. Mol Clin Oncol. 2015 Mar;3(2):420-424. doi: 10.3892/mco.2014.467. Epub 2014 Nov 25. PMID: 25798279; PMCID: PMC4360815.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2015 Mar;3(2):420-424. doi: 10.3892/mco.2014.467. Epub 2014 Nov 25.

Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis.

Molecular and clinical oncology

Huizhen Yang, Yun Ma, Zhida Liu, Zheng Wang, Baohui Han, Lijun Ma

Affiliations

  1. Department of Respiratory and Critical Care Medicine, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003.
  2. Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, P.R. China.

PMID: 25798279 PMCID: PMC4360815 DOI: 10.3892/mco.2014.467

Abstract

This study was conducted to compare the efficacy and safety of ifosfamide plus etoposide plus platinum (IEP) to that of etoposide plus platinum (EP) in patients with previously untreated small-cell lung cancer (SCLC). The Cochrane Library, Embase, MEDLINE and Chinese Biomedical Literature databases were searched to identify all randomized controlled trials comparing IEP to EP in patients with histologically proven SCLC. Two investigators independently assessed the quality of the relevant trials and extracted data. We analyzed the data using Review Manager software, version 4.2.8. A total of 4 trials with 447 previously untreated SCLC patients were included in this meta-analysis. The results of the meta-analysis indicated that there were no significant differences in the overall response [relative risk (RR) = 1.07, 95% confidence interval (CI): 0.97-1.19], 1-year survival rate (RR=1.22, 95% CI: 0.96-1.55) and 2-year survival rate (RR=1.52, 95% CI: 0.75-3.07) between the IEP and EP regimens. However, there were significant differences between the IEP and EP regimens regarding the incidence of grade 3/4 neutropenia (RR=1.52, 95% CI: 1.07-2.17) and grade 3/4 vomiting (RR=1.78, 95% CI: 1.02-3.11). In conclusion, our results suggested that IEP is not superior to EP regimen for the treatment of previously untreated SCLC, whereas the IEP regimen is associated with more severe hematological and gastrointestinal toxicities compared to EP. Therefore, the use of ifosfamide in multimodality treatment regimens requires further investigation.

Keywords: etoposide; ifosfamide; platinum; small-cell lung cancer

References

  1. Zhongguo Fei Ai Za Zhi. 2004 Jun 20;7(3):240-2 - PubMed
  2. Intern Med J. 2012 Dec;42(12 ):1297-309 - PubMed
  3. Cancer. 1987 Nov 15;60(10):2382-7 - PubMed
  4. Oncology. 1992;49(6):431-5 - PubMed
  5. Clin Oncol (R Coll Radiol). 2002 Oct;14(5):367-71 - PubMed
  6. Cancer Treat Rev. 1985 Mar;12(1):1-47 - PubMed
  7. J Clin Oncol. 1987 Dec;5(12):1880-9 - PubMed
  8. Semin Oncol. 1989 Feb;16(1 Suppl 3):9-18 - PubMed
  9. J Clin Oncol. 1995 Jul;13(7):1615-22 - PubMed
  10. Ann Oncol. 2010 May;21 Suppl 5:v120-5 - PubMed
  11. Zhongguo Fei Ai Za Zhi. 2004 Apr 20;7(2):151-3 - PubMed
  12. Eur J Cancer. 1994;30A(3):299-303 - PubMed
  13. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 - PubMed
  14. N Engl J Med. 1999 Jan 28;340(4):265-71 - PubMed
  15. Lancet. 2005 Oct 15-21;366(9494):1385-96 - PubMed
  16. Cancer. 1992 Feb 1;69(3):669-73 - PubMed
  17. J Clin Oncol. 1995 Oct;13(10 ):2594-9 - PubMed
  18. Cancer. 1998 Jan 15;82(2):301-8 - PubMed
  19. Br J Cancer. 2001 Jun 1;84(11):1447-52 - PubMed

Publication Types